Farallon Capital Exits Agios Pharma Stake as of Dec 31, 2023

TL;DR

**Farallon Capital is out of Agios Pharma, watch for potential stock impact.**

AI Summary

Farallon Capital Partners, L.P. filed an amended SC 13G/A on February 8, 2024, indicating a change in their beneficial ownership of Agios Pharmaceuticals, Inc. common stock as of December 31, 2023. This filing, an amendment to a previous Schedule 13G, shows that Farallon Capital Partners, L.P. is no longer reporting beneficial ownership of Agios Pharmaceuticals, Inc. This matters to investors because a significant institutional investor has exited or substantially reduced its position, which could signal a loss of confidence or a strategic portfolio reallocation, potentially impacting the stock's perceived value.

Why It Matters

This filing indicates a major institutional investor, Farallon Capital Partners, L.P., has divested its stake in Agios Pharmaceuticals, Inc., which could be interpreted negatively by the market.

Risk Assessment

Risk Level: medium — The exit of a significant institutional investor like Farallon Capital could lead to increased selling pressure or a decline in investor confidence for Agios Pharmaceuticals, Inc.

Analyst Insight

A smart investor would investigate the reasons behind Farallon Capital Partners, L.P.'s divestment from Agios Pharmaceuticals, Inc. and consider if this signals underlying issues before making any investment decisions.

Key Players & Entities

• Farallon Capital Partners, L.P. (company) — the reporting person who filed the SC 13G/A
• Agios Pharmaceuticals, Inc. (company) — the subject company whose securities are being reported
• December 31, 2023 (date) — the date of the event requiring the filing
• February 8, 2024 (date) — the filing date of the SC 13G/A

Forward-Looking Statements

• Agios Pharmaceuticals, Inc. stock price may experience downward pressure in the short term. (Agios Pharmaceuticals, Inc.) — medium confidence, target: Q1 2024
• Other institutional investors may re-evaluate their positions in Agios Pharmaceuticals, Inc. following Farallon's exit. (institutional investors) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie

Filing Documents

• agio_13ga.htm (SC 13G/A) — 423KB
• 0000908834-24-000046.txt ( ) — 425KB

From the Filing

SC 13G/A 1 agio_13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Agios Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00847X104 (Cusip Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following pages) Page 1 of 34 Pages Exhibit Index Found on Page 34 13G CUSIP No. 00847X104 1 NAMES OF REPORTING PERSONS Farallon Capital Partners, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ X ]** ** The reporting persons making this filing hold an aggregate of 4,167,602 Shares, which is 7.5% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page. 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER -0- 6 SHARED VOTING POWER 350,343 7 SOLE DISPOSITIVE POWER -0- 8 SHARED DISPOSITIVE POWER 350,343 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 350,343 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.6% 12 TYPE OF REPORTING PERSON (See Instructions) PN Page 2 of 34 Pages 13G CUSIP No. 00847X104 1 NAMES OF REPORTING PERSONS Farallon Capital Institutional Partners, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ X ]** ** The reporting persons making this filing hold an aggregate of 4,167,602 Shares, which is 7.5% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page. 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER -0- 6 SHARED VOTING POWER 427,810 7 SOLE DISPOSITIVE POWER -0- 8 SHARED DISPOSITIVE POWER 427,810 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 427,810 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.8% 12 TYPE OF REPORTING PERSON (See Instructions) PN Page 3 of 34 Pages 13G CUSIP No. 00847X104 1 NAMES OF REPORTING PERSONS Farallon Capital Institutional Partners II, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ X ]** ** The reporting persons making this filing hold an aggregate of 4,167,602 Shares, which is 7.5% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page. 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER -0- 6 SHARED VOTING POWER 128,895 7 SOLE DISPOSITIVE POWER -0- 8 SHARED DISPOSITIVE POWER 128,895 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 128,895 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.2% 12 TYPE OF REPORTING PERSON (See Instructions) PN Page 4 of 34 Pages 13G CUSIP No. 00847X104 1 NAMES OF REPORTING PERSONS Farallon Capital Institutional Partners III, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ X ]** ** The reporting persons making this filing hold an aggregate of 4,167,602 Shares, which is 7.5% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page. 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER -0- 6 SHARED VOTING POWER 51,359 7 SOLE DISPOSITIVE POWER -0- 8 SHARED DIS

View Full Filing

View this SC 13G/A filing on SEC EDGAR